Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst
TipRanks (Sat, 28-Mar 10:37 AM ET)
Abivax SA (0RA9) Receives a Rating Update from a Top Analyst
TipRanks (Thu, 26-Mar 3:39 AM ET)
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim
TipRanks (Wed, 25-Mar 6:59 AM ET)
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Globe Newswire (Mon, 23-Mar 4:05 PM ET)
Globe Newswire (Sat, 21-Feb 6:00 AM ET)
Abivax Provides 2026 Corporate Outlook
Globe Newswire (Wed, 7-Jan 4:05 PM ET)
Obefazimod Shows Potential Anti-Fibrotic Effect as Abivax Presents Expansive Data at ECCO 2026
Market Chameleon (Thu, 18-Dec 3:46 AM ET)
Abivax Extends Cash Runway to Q4 2027 After Public Offering Bolsters Financial Position
Market Chameleon (Tue, 16-Dec 2:06 AM ET)
Abivax's Obefazimod Shows Promising Patient-Reported Outcomes in Ulcerative Colitis Phase 3 Trials
Market Chameleon (Tue, 4-Nov 2:22 AM ET)
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Abivax SA - American Depositary Shares trades on the NASDAQ stock market under the symbol ABVX.
As of March 30, 2026, ABVX stock price declined to $101.32 with 687,294 million shares trading.
ABVX has a beta of 2.19, meaning it tends to be more sensitive to market movements. ABVX has a correlation of 0.03 to the broad based SPY ETF.
ABVX has a market cap of $8.02 billion. This is considered a Mid Cap stock.
Last quarter Abivax SA - American Depositary Shares reported $5 million in Revenue and -$5.45 earnings per share. This fell short of revenue expectation by $-348,000 and missed earnings estimates by -$.54.
The top ETF exchange traded funds that ABVX belongs to (by Net Assets): IBB, MSSM, FRTY, ONEQ, AADR.
ABVX has outperformed the market in the last year with a return of +1385.6%, while the SPY ETF gained +12.8%. However, in the most recent history, ABVX shares have underperformed the stock market with its stock returning -28.8% in the last 3 month period and -12.3% for the last 2 week period, while SPY has returned -8.1% and -4.3%, respectively.
ABVX support price is $98.69 and resistance is $106.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABVX shares will trade within this expected range on the day.